Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with ...
Aug 26, 2020
0
36